JP2024105479A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024105479A5 JP2024105479A5 JP2024076658A JP2024076658A JP2024105479A5 JP 2024105479 A5 JP2024105479 A5 JP 2024105479A5 JP 2024076658 A JP2024076658 A JP 2024076658A JP 2024076658 A JP2024076658 A JP 2024076658A JP 2024105479 A5 JP2024105479 A5 JP 2024105479A5
- Authority
- JP
- Japan
- Prior art keywords
- cell population
- hematopoietic
- hematopoietic cell
- cells
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762551075P | 2017-08-28 | 2017-08-28 | |
| US62/551,075 | 2017-08-28 | ||
| PCT/US2018/048317 WO2019046285A1 (en) | 2017-08-28 | 2018-08-28 | CD33 EXON 2 DONOR STEM CELLS FOR USE WITH CD33 TARGETING AGENTS |
| JP2020511435A JP2020531535A (ja) | 2017-08-28 | 2018-08-28 | Cd33標的剤と共に使用するためのcd33エクソン2欠損型ドナー幹細胞 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511435A Division JP2020531535A (ja) | 2017-08-28 | 2018-08-28 | Cd33標的剤と共に使用するためのcd33エクソン2欠損型ドナー幹細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024105479A JP2024105479A (ja) | 2024-08-06 |
| JP2024105479A5 true JP2024105479A5 (cg-RX-API-DMAC7.html) | 2024-11-01 |
Family
ID=65525985
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511435A Pending JP2020531535A (ja) | 2017-08-28 | 2018-08-28 | Cd33標的剤と共に使用するためのcd33エクソン2欠損型ドナー幹細胞 |
| JP2024076658A Pending JP2024105479A (ja) | 2017-08-28 | 2024-05-09 | Cd33標的剤と共に使用するためのcd33エクソン2欠損型ドナー幹細胞 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511435A Pending JP2020531535A (ja) | 2017-08-28 | 2018-08-28 | Cd33標的剤と共に使用するためのcd33エクソン2欠損型ドナー幹細胞 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11718659B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3676372A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2020531535A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019046285A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL258491B2 (en) | 2015-10-16 | 2023-09-01 | Univ Columbia | Preparations and methods for inhibiting antigens of a particular lineage |
| KR102709603B1 (ko) | 2017-02-28 | 2024-09-27 | 보르 바이오파마 인크. | 계통 특이적 단백질의 억제를 위한 조성물 및 방법 |
| EP3676372A4 (en) * | 2017-08-28 | 2021-06-02 | The Trustees of Columbia University in the City of New York | CD33 EXON 2 DEFICIENT DONOR STEM CELLS FOR USE WITH AGENTS AGAINST CD33 |
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| US11866494B2 (en) * | 2018-08-31 | 2024-01-09 | Innovative Cellular Therapeutics Holdings, Ltd. | CAR T therapy through uses of co-stimulation |
| JP7784707B2 (ja) * | 2019-01-16 | 2025-12-12 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | 系統特異的抗原の阻害のための組成物および方法 |
| AU2020280103A1 (en) | 2019-05-23 | 2021-12-23 | Vor Biopharma Inc. | Compositions and methods for CD33 modification |
| AU2020338011A1 (en) | 2019-08-28 | 2022-03-10 | Vor Biopharma Inc. | Compositions and methods for CLL1 modification |
| WO2021041977A1 (en) | 2019-08-28 | 2021-03-04 | Vor Biopharma, Inc. | Compositions and methods for cd123 modification |
| US12551560B2 (en) | 2019-09-09 | 2026-02-17 | Scribe Therapeutics Inc. | Compositions and methods for use in immunotherapy |
| EP4048790A4 (en) * | 2019-10-22 | 2024-03-27 | Fred Hutchinson Cancer Center | BASE EDITOR-MEDIATED CD33 REDUCTION FOR SELECTIVE PROTECTION OF THERAPEUTIC CELLS |
| CN116157135A (zh) * | 2020-06-03 | 2023-05-23 | 纽约市哥伦比亚大学理事会 | 使用基于crispr的碱基编辑器系统抑制谱系特异性抗原的组合物和方法 |
| EP4204564A1 (en) | 2020-08-28 | 2023-07-05 | Vor Biopharma Inc. | Compositions and methods for cd123 modification |
| EP4204565A1 (en) | 2020-08-28 | 2023-07-05 | Vor Biopharma Inc. | Compositions and methods for cll1 modification |
| WO2022056489A1 (en) | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Compositions and methods for cd38 modification |
| EP4211245A1 (en) | 2020-09-14 | 2023-07-19 | Vor Biopharma Inc. | Compositions and methods for cd5 modification |
| WO2022061115A1 (en) | 2020-09-18 | 2022-03-24 | Vor Biopharma Inc. | Compositions and methods for cd7 modification |
| WO2022067240A1 (en) | 2020-09-28 | 2022-03-31 | Vor Biopharma, Inc. | Compositions and methods for cd6 modification |
| WO2022072643A1 (en) | 2020-09-30 | 2022-04-07 | Vor Biopharma Inc. | Compositions and methods for cd30 gene modification |
| CA3199623A1 (en) * | 2020-10-27 | 2022-05-05 | Vor Biopharma Inc. | Compositions and methods for treating hematopoietic malignancy |
| CN116600821A (zh) * | 2020-10-27 | 2023-08-15 | Vor生物制药股份有限公司 | 用于治疗造血系统恶性肿瘤的组合物和方法 |
| WO2022094245A1 (en) | 2020-10-30 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for bcma modification |
| AU2021413252A1 (en) | 2020-12-31 | 2023-06-08 | Vor Biopharma Inc. | Compositions and methods for cd34 gene modification |
| CN115443333B (zh) * | 2021-04-27 | 2025-04-25 | 上海驯鹿生物技术有限公司 | 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 |
| PE20252304A1 (es) * | 2021-04-28 | 2025-09-22 | Eisai Randd Man Co Ltd | Oligonucleotidos antisentido y su uso para el tratamiento de trastornos neurodegenerativos |
| EP4430186A1 (en) | 2021-11-09 | 2024-09-18 | Vor Biopharma Inc. | Compositions and methods for erm2 modification |
| WO2024015925A2 (en) | 2022-07-13 | 2024-01-18 | Vor Biopharma Inc. | Compositions and methods for artificial protospacer adjacent motif (pam) generation |
| IL320040A (en) * | 2022-10-05 | 2025-06-01 | Musc Found For Res Dev | Superantigen conjugate vaccine for cancer treatment |
| WO2024168312A1 (en) * | 2023-02-09 | 2024-08-15 | Vor Biopharma Inc. | Methods for treating hematopoietic malignancy |
| WO2025030010A1 (en) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6831777B2 (ja) | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Cd33キメラ抗原受容体を使用する癌の処置 |
| US10201606B2 (en) * | 2014-11-26 | 2019-02-12 | Miltenyi Biotec Gmbh | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
| IL258491B2 (en) * | 2015-10-16 | 2023-09-01 | Univ Columbia | Preparations and methods for inhibiting antigens of a particular lineage |
| EP3439700A4 (en) * | 2016-04-06 | 2020-01-01 | University of Florida Research Foundation, Inc. | BIOMARKER FOR ANTILEUCEMIC THERAPY |
| KR102709603B1 (ko) * | 2017-02-28 | 2024-09-27 | 보르 바이오파마 인크. | 계통 특이적 단백질의 억제를 위한 조성물 및 방법 |
| EP3676372A4 (en) * | 2017-08-28 | 2021-06-02 | The Trustees of Columbia University in the City of New York | CD33 EXON 2 DEFICIENT DONOR STEM CELLS FOR USE WITH AGENTS AGAINST CD33 |
-
2018
- 2018-08-28 EP EP18852123.1A patent/EP3676372A4/en not_active Withdrawn
- 2018-08-28 US US16/640,086 patent/US11718659B2/en active Active
- 2018-08-28 JP JP2020511435A patent/JP2020531535A/ja active Pending
- 2018-08-28 WO PCT/US2018/048317 patent/WO2019046285A1/en not_active Ceased
-
2023
- 2023-06-06 US US18/206,269 patent/US20240166721A1/en not_active Abandoned
-
2024
- 2024-05-09 JP JP2024076658A patent/JP2024105479A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Diorio et al. | Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks | |
| Voehringer et al. | Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1) | |
| Yang et al. | Challenges and opportunities of allogeneic donor-derived CAR T cells | |
| JP2020531535A5 (cg-RX-API-DMAC7.html) | ||
| Tomuleasa et al. | Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia | |
| AU2025205147A1 (en) | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies | |
| Clark et al. | Cultured human follicular dendritic cells. Growth characteristics and interactions with B lymphocytes | |
| Veuillen et al. | Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy | |
| Oh et al. | Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia | |
| US12398402B2 (en) | Reducing CD33 expression to selectively protect therapeutic cells | |
| CN113227141A (zh) | 抗cd33免疫细胞癌症疗法 | |
| EP3757133A1 (en) | Isolated chimeric antigen receptor, modified t cell comprising same and use thereof | |
| US20250041339A1 (en) | Engineered Pan-Leukocyte Antigen CD45 to Facilityate CAR T Cell Therapy | |
| Kujawski et al. | Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation | |
| JP2023528415A5 (cg-RX-API-DMAC7.html) | ||
| JP2024515920A (ja) | 固形腫瘍標的化骨格を有する細胞及びその使用 | |
| Yu et al. | In vivo persistence of genetically modified T cells generated ex vivo using the fibronectin CH296 stimulation method | |
| Dourthe et al. | CAR T-cells for T-cell acute lymphoblastic leukemia | |
| US12295973B2 (en) | Luteinizing hormone receptor binding agents and luteinizing hormone agonists to identify, expand, ablate and modify stem cells | |
| US20250170182A1 (en) | Epitope engineering of cell-surface receptors | |
| US20220195441A1 (en) | Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias | |
| WO2023250433A2 (en) | Engineered human t cells comprising a switchable chimeric antigen cell surface receptor and methods for generating them | |
| US20240139321A1 (en) | Universal car-t cell targeting gd2, preparation method therefor, and application thereof | |
| EP4295860A1 (en) | Engineered human t cells comprising a switchable chimeric antigen cell surface receptor and methods for generating them | |
| WO2022040277A1 (en) | Constitutively active tcf1 to promote memory-associated traits in car t cells |